Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis - European Medical Journal

Continue

Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis

Neurology
Download PDF

This satellite symposium took place on 29th May 2016, as part of the 2nd Congress of the European Academy of Neurology (EAN), Copenhagen, Denmark

Chairperson:
Per Soelberg Sørensen1
Speakers:
Wiendl,2 Andreas Lysandropoulos,3 Andrew Chan4

1. Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark
2. Department of Neurology, University Hospital of Münster, Münster, Germany
3. Neuroimmunology Unit, Department of Neurology, University Hospital Erasme, Brussels, Belgium
4. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany

Disclosure:

Prof Per Soelberg Sørensen has received personal compensation for serving on scientific advisory boards, steering committees, or independent data monitoring boards for Biogen, Merck Serono, Novartis, Genzyme, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, medDay Pharmaceuticals, and Forward Pharma and has received speaker honoraria from Biogen, Merck Serono, Teva Pharmaceutical Industries Ltd., Genzyme, and Novartis. His department has received research support from Biogen Merck Serono, TEVA, Sanofi-Aventis/Genzyme, Novartis, Bayer, RoFAR, Roche, the Danish Multiple Sclerosis Society, the Danish Medical Research Council, and the European Union Sixth Framework Programme: Life sciences, and Genomics and Biotechnology for health. Prof Heinz Wiendl has received honoraria for lecturing and travel expenses for attending meetings from Bayer Healthcare, Biogen, Elan Corporation, Lilly, Lundbeck, Merck Serono, Novartis, Sanofi Genzyme, and Teva Neuroscience, has received compensation for serving as a consultant for Biogen, Merck Serono, Novartis Pharma, and Sanofi Genzyme, and research support from Bayer Schering Pharma, Biogen, Elan Corporation, Merck Serono, Novartis, Novo Nordisk, and Sanofi Genzyme. Dr Andreas Lysandropoulos has received educational grants and honoraria as a speaker and member of advisory boards for Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, and Teva. Prof Andrew Chan has received personal compensation (speakers honoraria and advisory board) from Bayer, Biogen, Sanofi Genzyme, Merck, Novartis, Roche, and Teva, and research support from Biogen, Sanofi Genzyme, and Novartis.

Acknowledgements:

Writing assistance was provided by Dr Joan Thomas of ApotheCom.

Support:

The symposium and publication of this article was sponsored by Sanofi Genzyme. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily Sanofi Genzyme.

Citation:
EMJ Neurol. ;4[1]:36-44. DOI/10.33590/emjneurol/10310675. https://doi.org/10.33590/emjneurol/10310675.
Keywords:
EAN, European Association of Neurology

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Brain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment protocols for MS so that early and appropriate management can be initiated to preserve brain volume and function.

Prof Per Solberg Sørensen chaired the symposium and welcomed the speakers. Prof Heinz Wiendl gave a presentation on BVL in MS and described its underlying pathophysiology. Dr Andreas Lysandropoulos illustrated how information on BVL is clinically relevant and can be taken from clinical studies to assist clinical practice and decision-making. The final presentation was given by Prof Andrew Chan who highlighted the important role of brain atrophy in decision-making for early treatment and presented recent data for two treatments for MS: teriflunomide and the monoclonal antibody alemtuzumab. The symposium was concluded by a short question and answer session.

Please view the full content in the PDF above. 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.